H.R. 5663House116th Congress (2019-2021)Enacted

Safeguarding Therapeutics Act

Introduced January 21, 2020

AI-Generated Summary

Updated April 14, 2026 at 10:35 AM UTC

The Safeguarding Therapeutics Act amends the Federal Food, Drug, and Cosmetic Act to give the Secretary of Health and Human Services, through the FDA Commissioner, authority to destroy counterfeit medical devices. It also creates a definition of “counterfeit device” and sets up procedural rules for notice and due‑process before destruction. The changes affect manufacturers, importers, and owners of medical devices that may be counterfeit.

Key Provisions

  • Adds “counterfeit device” to the list of items the Secretary of Health and Human Services can order destroyed, alongside counterfeit drugs.
  • Allows HHS to destroy low‑value counterfeit devices (valued at $2,500 or less) without requiring export, after providing notice and an opportunity to be heard.
  • Requires HHS to issue regulations that give owners or consignees due process before a device is destroyed, including notice and a chance to present testimony.
  • Defines a “counterfeit device” as one that bears unauthorized trademarks, trade names, or other identifying marks, or is made using a design that falsely appears to come from a different manufacturer, processor, packer, or distributor.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

27 earlier actions
Became Law Latest Action

Became Public Law No: 116-304.

January 5, 2021

View full timeline
HouseIntro Referral

Introduced in House

January 21, 2020

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

January 21, 2020

HouseCommittee

Referred to the Subcommittee on Health.

January 22, 2020

HouseCommittee

Ordered to be Reported by Voice Vote.

March 11, 2020

HouseCommittee

Subcommittee Consideration and Mark-up Session Held.

March 11, 2020

HouseCommittee

Committee Consideration and Mark-up Session Held.

July 15, 2020

HouseCommittee

Ordered to be Reported (Amended) by Voice Vote.

July 15, 2020

HouseCommittee

Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-512.

September 17, 2020

HouseCalendars

Placed on the Union Calendar, Calendar No. 412.

September 17, 2020

HouseFloor

Mrs. Dingell moved to suspend the rules and pass the bill, as amended.

September 21, 2020 • 6:48 PM

HouseFloor

Considered under suspension of the rules. (consideration: CR H4635-4636)

September 21, 2020 • 6:48 PM

HouseFloor

DEBATE - The House proceeded with forty minutes of debate on H.R. 5663.

September 21, 2020 • 6:48 PM

HouseFloor

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

September 21, 2020 • 6:57 PM

HouseFloor

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4635)

September 21, 2020 • 6:57 PM

HouseFloor

Motion to reconsider laid on the table Agreed to without objection.

September 21, 2020 • 6:57 PM

SenateIntro Referral

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

September 22, 2020

SenateFloor

Measure laid before Senate by unanimous consent. (consideration: CR S7286)

December 8, 2020

SenateCommittee

Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.

December 8, 2020

SenateFloor

Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7286)

December 8, 2020

SenateFloor

Message on Senate action sent to the House.

December 9, 2020

HouseResolving Differences

Mrs. Dingell asked unanimous consent that the House agree to the Senate amendment.

December 10, 2020 • 12:12 PM

HouseFloor

Mrs. Dingell asked unanimous consent to take the bill, H.R. 5663 from the Speaker's Table and agree to the Senate amendment. (consideration: CR H7131)

December 10, 2020 • 12:12 PM

HouseNot Used

Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to without objection.(text: CR H7131)

December 10, 2020

HouseResolving Differences

On motion that the House agree to the Senate amendment Agreed to without objection. (text: CR H7131)

December 10, 2020 • 12:13 PM

HouseResolving Differences

Motion to reconsider laid on the table Agreed to without objection.

December 10, 2020 • 12:13 PM

President

Presented to President.

December 24, 2020

Became Law

Signed by President.

January 5, 2021

Became Law

Became Public Law No: 116-304.

January 5, 2021

Amendments

1 amendment

Offered to this bill

Bill Text

7 versions available

Reading Mode
Latest
Enrolled BillPublication date not provided

One Hundred Sixteenth Congress of the United States of America

At the Second Session

Begun and held at the City of Washington on Friday, the third day of January, two thousand and twenty

H. R. 5663

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to give authority to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to destroy counterfeit devices.

1.

Short title

This Act may be cited as the Safeguarding Therapeutics Act.

2.

Authority to destroy counterfeit devices

(a)

In general

Section 801(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a)) is amended—

(1)

in the fourth sentence, by inserting or counterfeit device after counterfeit drug; and

(2)

by striking The Secretary of the Treasury shall cause the destruction of and all that follows through liable for costs pursuant to subsection (c). and inserting the following: The Secretary of the Treasury shall cause the destruction of any such article refused admission unless such article is exported, under regulations prescribed by the Secretary of the Treasury, within 90 days of the date of notice of such refusal or within such additional time as may be permitted pursuant to such regulations, except that the Secretary of Health and Human Services may destroy, without the opportunity for export, any drug or device refused admission under this section, if such drug or device is valued at an amount that is $2,500 or less (or such higher amount as the Secretary of the Treasury may set by regulation pursuant to section 498(a)(1) of the Tariff Act of 1930 (19 U.S.C. 1498(a)(1))) and was not brought into compliance as described under subsection (b). The Secretary of Health and Human Services shall issue regulations providing for notice and an opportunity to appear before the Secretary of Health and Human Services and introduce testimony, as described in the first sentence of this subsection, on destruction of a drug or device under the seventh sentence of this subsection. The regulations shall provide that prior to destruction, appropriate due process is available to the owner or consignee seeking to challenge the decision to destroy the drug or device. Where the Secretary of Health and Human Services provides notice and an opportunity to appear and introduce testimony on the destruction of a drug or device, the Secretary of Health and Human Services shall store and, as applicable, dispose of the drug or device after the issuance of the notice, except that the owner and consignee shall remain liable for costs pursuant to subsection (c)..

(b)

Definition

Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)) is amended—

(1)

by redesignating subparagraphs (1), (2), and (3) as clauses (A), (B), and (C), respectively; and

(2)

after making such redesignations—

(A)

by striking (h) The term and inserting (h)(1) The term; and

(B)

by adding at the end the following:

(2)

The term counterfeit device means a device which, or the container, packaging, or labeling of which, without authorization, bears a trademark, trade name, or other identifying mark or imprint, or any likeness thereof, or is manufactured using a design, of a device manufacturer, processor, packer, or distributor other than the person or persons who in fact manufactured, processed, packed, or distributed such device and which thereby falsely purports or is represented to be the product of, or to have been packed or distributed by, such other device manufacturer, processor, packer, or distributor.

.

Speaker of the House of Representatives.

Vice President of the United States and President of the Senate.